Belangrijke wijziging van behandelrichtlijn ‘Diabetes mellitus type 2’
| Autor: | Serné, Erik H., IJzerman, Richard G., Krijger-Dijkema, J. M., Burger, Koert N. J., Hart, H. E., Klein Woolthuis, Erwin P., Janssen, Paul G. H., Wiersma, Tjerk |
|---|---|
| Přispěvatelé: | Internal medicine, ACS - Diabetes & metabolism, ACS - Microcirculation, Amsterdam Gastroenterology Endocrinology Metabolism |
| Jazyk: | Dutch; Flemish |
| Rok vydání: | 2021 |
| Zdroj: | Nederlands Tijdschrift voor Geneeskunde, 165. Bohn Stafleu van Loghum Serné, E H, IJzerman, R G, Krijger-Dijkema, J M, Burger, K N J, Hart, H E, Klein Woolthuis, E P, Janssen, P G H & Wiersma, T 2021, ' Belangrijke wijziging van behandelrichtlijn ‘Diabetes mellitus type 2’ ', Nederlands Tijdschrift voor Geneeskunde, vol. 165 . |
| ISSN: | 0028-2162 |
| Popis: | Recent trials of two classes of glucose-lowering drugs (SGLT2 inhibitors and GLP1RAs) have shown consistent cardiovascular and renal benefits that appear independent of glycaemic control. These results have prompted the Dutch College of General Practitioners (NHG) together with the Dutch Society of Internal Medicine (NIV) to update the treatment algorithm in patients with type 2 diabetes mellitus (T2D) at very high CVD risk. The use of SGLT2 inhibitors or GLP1RAs is now recommended in 3 groups of people with T2D. 1. patients with established CVD; 2. Patients with chronic kidney disease and a moderately to high CVD risk according to KDIGO; 3. patients with heart failure with reduced ejection fraction (HFrEF). Treatment algorithms differ for drug-naïve and drug-treated patients with T2D. In both drug-naïve and drug-treated patients the use of a SGLT2 inhibitor respectively as monotherapy or add-on is recommended as first step. If HbA1c is above the individual target, metformin will be added in drug-naive patients whereas GLP1-RAs could be considered in drug-treated patients. GLP1-RAs should also be considered when SGLT2-inhibitors are contraindicated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|